Hi Tech Pharmacal (NAS: HITK) reported earnings on Sep. 5. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended July 31 (Q1), Hi Tech Pharmacal missed estimates on revenues and missed estimates on earnings per share.
Compared to the prior-year quarter, revenue shrank and GAAP earnings per share dropped significantly.
Margins shrank across the board.
Hi Tech Pharmacal chalked up revenue of $52.0 million. The four analysts polled by S&P Capital IQ anticipated revenue of $57.6 million on the same basis. GAAP reported sales were 7.4% lower than the prior-year quarter's $56.2 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.44. The four earnings estimates compiled by S&P Capital IQ predicted $0.68 per share. GAAP EPS of $0.44 for Q1 were 58% lower than the prior-year quarter's $1.05 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 48.7%, 1,040 basis points worse than the prior-year quarter. Operating margin was 16.3%, 1,980 basis points worse than the prior-year quarter. Net margin was 11.5%, 1,300 basis points worse than the prior-year quarter.
Next quarter's average estimate for revenue is $57.1 million. On the bottom line, the average EPS estimate is $0.59.
Next year's average estimate for revenue is $238.1 million. The average EPS estimate is $2.64.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 205 members out of 223 rating the stock outperform, and 18 members rating it underperform. Among 52 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 45 give Hi Tech Pharmacal a green thumbs-up, and seven give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Hi Tech Pharmacal is outperform, with an average price target of $37.83.
Add Hi Tech Pharmacal to My Watchlist.
The article The Gory Details on Hi Tech Pharmacal's Double Fumble originally appeared on Fool.com.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.